Show simple item record

dc.contributor.authorOtsui, Kazunori
dc.contributor.authorGorog, Diana A
dc.contributor.authorYamamoto, Junichiro
dc.contributor.authorYoshioka, Takayuki
dc.contributor.authorIwata, Sachiyo
dc.contributor.authorSuzuki, Atsushi
dc.contributor.authorOzawa, Toru
dc.contributor.authorTakei, Asumi
dc.contributor.authorInoue, Nobutaka
dc.date.accessioned2019-05-10T14:04:50Z
dc.date.available2019-05-10T14:04:50Z
dc.date.issued2015-12-08
dc.identifier.citationOtsui , K , Gorog , D A , Yamamoto , J , Yoshioka , T , Iwata , S , Suzuki , A , Ozawa , T , Takei , A & Inoue , N 2015 , ' Global Thrombosis Test - a possible monitoring system for the effects and safety of dabigatran ' , Thrombosis Journal , vol. 13 , no. 39 . https://doi.org/10.1186/s12959-015-0069-6
dc.identifier.issn1477-9560
dc.identifier.otherPURE: 13240292
dc.identifier.otherPURE UUID: 74f5c42e-8cf6-4f6f-bbf0-23aac370d403
dc.identifier.otherPubMed: 26648789
dc.identifier.otherPubMedCentral: PMC4672538
dc.identifier.otherScopus: 84949216469
dc.identifier.urihttp://hdl.handle.net/2299/21324
dc.description© Otsui et al. 2015
dc.description.abstractBACKGROUND: Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of stroke in patients with non-valvular atrial fibrillation (NVAF). The advantage of dabigatran over WF is that monitoring is not required; however, a method to monitor the effect and the safety of dabigatran is not currently available. The Global Thrombosis Test (GTT) is a novel method to assess both clot formation and lysis activities under physiological conditions. OBJECTIVE: The aim of this study was to evaluate whether treatment with dabigatran might affect shear-induced thrombi (occlusion time [OT], sec) by the GTT, and to investigate the possibility that the GTT could be useful as a monitoring system for dabigatran. PATIENTS/METHODS: The study population consisted of 50 volunteers and 43 NVAF patients on WF therapy, who were subsequently switched to dabigatran. Using the GTT, the thrombotic status was assessed one day before and 1 month after switching anticoagulation from WF to dabigatran. RESULTS: The OT was 524.9 ± 17.0 sec in volunteers whereas that of NVAF patients on WF therapy was 581.7 ± 26.3 sec. The switch from WF to dabigatran significantly prolonged OT (784.5 ± 19.3 sec). One patient on WF therapy and 12 patients on dabigatran therapy were shown to have OT > 900 sec. CONCLUSION: The GTT could be used to assess the risk of dabigatran-related bleeding complications.en
dc.format.extent5
dc.language.isoeng
dc.relation.ispartofThrombosis Journal
dc.subjectJournal Article
dc.titleGlobal Thrombosis Test - a possible monitoring system for the effects and safety of dabigatranen
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Pharmacy, Pharmacology and Postgraduate Medicine
dc.description.statusPeer reviewed
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1186/s12959-015-0069-6
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record